SPYRE THERAPEUTICS, INC. Number of Reportable Segments
SPYRE THERAPEUTICS, INC. (SYRE) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment.
- SPYRE THERAPEUTICS, INC. number of reportable segments for fiscal 2025 was 1.00 segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-19 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |